Innoviva, Inc. (INVA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1156036,
    "name": "Innoviva, Inc.",
    "stock_name": "Innoviva, Inc.",
    "full_name": "Innoviva, Inc.",
    "name_url": "stocks-analysis/innoviva-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "20.80",
    "chg": -0.18,
    "chgp": "-0.86%",
    "dir": -1,
    "prev_price": "20.98",
    "mcapval": "1,944.23",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US45781M1018",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "574.59 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/innoviva-inc-1156036-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Innoviva, Inc. Experiences Valuation Adjustment Amidst Competitive Market Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/innoviva-inc-sees-valuation-grade-shift-from-expensive-to-very-expensive-3667055",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/InnovivaInc_valuationdot_3667055.png",
        "date": "2025-11-03 15:44:25",
        "description": "Innoviva, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 15 and a strong return on capital employed at 28.07%. Compared to peers, Innoviva's metrics reveal a challenging market position, with its stock price showing slight variability and a year-over-year decline against the S&P 500's gains."
      },
      {
        "title": "Innoviva, Inc. Forms Death Cross, Signaling Potential Bearish Trend Ahead",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/innoviva-inc-forms-death-cross-signaling-potential-bearish-trend-ahead-3658972",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/InnovivaInc_dealthcross_3658972.png",
        "date": "2025-10-30 15:34:25",
        "description": "Innoviva, Inc. has recently encountered a technical event known as a Death Cross, indicating a potential shift in market sentiment. Current indicators reflect a bearish outlook, with the stock underperforming the S&P 500 over the past year, raising concerns about its competitive position in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Is Innoviva, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-innoviva-inc-overvalued-or-undervalued-3637788",
        "imagepath": "",
        "date": "2025-10-21 12:08:58",
        "description": "As of 17 October 2025, the valuation grade for Innoviva, Inc. has moved from attractive to expensive, indicating a shift towards overvaluation. The company appears to be overvalued based on its current P/E ratio of 15, which is lower than the peer average of approximately 16.41, and an EV to EBITDA ratio of 9.21, which is also competitive compared to its peers. Additionally, the PEG ratio stands at a notably low 0.20, suggesting that the stock may not be justified at its current price level.\n\nIn comparison to its peers, MannKind Corp. has a significantly higher P/E ratio of 38.35, while Ligand Pharmaceuticals, Inc. shows a negative P/E of -67.27, highlighting the varying valuations within the industry. The stock has underperformed against the S&P 500 over multiple periods, with a 1-year return of -14.38% compared to the index's 14.08%, reinforcing the notion that Innoviva, Inc. may not be a compelling inves..."
      },
      {
        "title": "Innoviva, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Market Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/innoviva-inc-sees-valuation-grade-shift-from-attractive-to-expensive-amid-stock-decline-3640733",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/InnovivaInc_valuationdot_3640733.png",
        "date": "2025-10-20 16:18:53",
        "description": "Innoviva, Inc. has recently adjusted its valuation, with a P/E ratio of 15 and a Price to Book Value of 3.16. The company demonstrates strong operational efficiency, reflected in its EV to EBIT and EV to EBITDA ratios, alongside notable returns on capital and equity compared to its peers."
      },
      {
        "title": "Is Innoviva, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-innoviva-inc-overvalued-or-undervalued-3634656",
        "imagepath": "",
        "date": "2025-10-20 12:26:22",
        "description": "As of 17 October 2025, the valuation grade for Innoviva, Inc. has moved from attractive to expensive, indicating a shift towards overvaluation. The company is currently considered overvalued based on its P/E ratio of 15, which is lower than its peer average of approximately 16.41, and an EV to EBITDA ratio of 9.21, which is also competitive compared to its peers. Additionally, the PEG ratio stands out at 0.20, suggesting strong growth potential relative to its price.\n\nIn comparison to its peers, Ligand Pharmaceuticals, Inc. has a significantly higher P/E ratio of 67.27, while MannKind Corp. shows a P/E of 38.35, both indicating a higher valuation in the market. Despite Innoviva's strong ROCE of 28.07% and ROE of 20.43%, its recent stock performance has lagged behind the S&P 500, with a year-to-date return of -0.46% compared to the S&P 500's 13.30%. This underperformance reinforces the notion that Innoviva, ..."
      },
      {
        "title": "Is Innoviva, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-innoviva-inc-overvalued-or-undervalued-3632197",
        "imagepath": "",
        "date": "2025-10-19 12:03:55",
        "description": "As of 17 October 2025, the valuation grade for Innoviva, Inc. has moved from attractive to expensive, indicating a shift towards overvaluation. The company appears overvalued based on its current metrics, with a P/E ratio of 15, a Price to Book Value of 3.16, and an EV to EBITDA of 9.21. In comparison, its peer Ligand Pharmaceuticals, Inc. has a significantly higher P/E ratio of 16.41, while MannKind Corp. shows a P/E of 38.35, suggesting that Innoviva's valuation may not be justified relative to its peers.\n\nThe company's ROCE stands at a strong 28.07%, and its ROE is 20.43%, indicating solid profitability. However, these strengths are overshadowed by its high valuation ratios. Although specific return data is not available, the absence of comparative performance metrics against the S&P 500 adds to the uncertainty surrounding its current valuation status. Overall, Innoviva, Inc. is deemed overvalued in the ..."
      },
      {
        "title": "Innoviva, Inc. Stock Plummets to New 52-Week Low of $16.52",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/innoviva-inc-stock-plummets-to-new-52-week-low-of-1652-3626644",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/InnovivaInc_priceRelatedfactors_3626644.png",
        "date": "2025-10-16 18:21:32",
        "description": "Innoviva, Inc. has reached a new 52-week low of USD 16.52, significantly down from its high of USD 22. The company, with a market cap of USD 1,944 million, shows a 9.1% gain over the past year, lower than the S&P 500's 13.39%. Innoviva has a P/E ratio of 15.00 and a low debt-to-equity ratio of 0.03, indicating conservative leverage. The return on equity is 16.58%, but the company does not offer dividends."
      },
      {
        "title": "Innoviva, Inc. Hits 52-Week Low at USD 16.59 Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/innoviva-inc-hits-52-week-low-at-usd-1659-amid-market-volatility-3622801",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/InnovivaInc_priceRelatedfactors_3622801.png",
        "date": "2025-10-15 17:01:14",
        "description": "Innoviva, Inc. has reached a new 52-week low of USD 16.59, contrasting with its 1-year performance of 4.58%. With a market cap of USD 1,944 million, a P/E ratio of 15.00, and a low debt-to-equity ratio of 0.03, the company emphasizes reinvestment over dividends."
      },
      {
        "title": "Innoviva, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Fluctuations",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/innoviva-inc-technical-trend-shifts-from-mildly-bullish-to-sideways-amid-stock-decline-3559556",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/InnovivaInc_technicaldot_3559556.png",
        "date": "2025-09-23 16:00:44",
        "description": "Innoviva, Inc., a small-cap pharmaceutical company, has experienced stock fluctuations, with a recent closing price of $19.19. The stock's performance has varied, showing a year-to-date return of 9.74%, while trailing behind the S&P 500. Recent evaluations highlight the company's position amid market challenges."
      }
    ],
    "total": 18,
    "sid": "1156036",
    "stock_news_url": "https://www.marketsmojo.com/news/innoviva-inc-1156036"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Innoviva, Inc. Experiences Valuation Adjustment Amidst Competitive Market Landscape

2025-11-03 15:44:25

Innoviva, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 15 and a strong return on capital employed at 28.07%. Compared to peers, Innoviva's metrics reveal a challenging market position, with its stock price showing slight variability and a year-over-year decline against the S&P 500's gains.

Innoviva, Inc. Forms Death Cross, Signaling Potential Bearish Trend Ahead

2025-10-30 15:34:25

Innoviva, Inc. has recently encountered a technical event known as a Death Cross, indicating a potential shift in market sentiment. Current indicators reflect a bearish outlook, with the stock underperforming the S&P 500 over the past year, raising concerns about its competitive position in the Pharmaceuticals & Biotechnology sector.

Is Innoviva, Inc. overvalued or undervalued?

2025-10-21 12:08:58

As of 17 October 2025, the valuation grade for Innoviva, Inc. has moved from attractive to expensive, indicating a shift towards overvaluation. The company appears to be overvalued based on its current P/E ratio of 15, which is lower than the peer average of approximately 16.41, and an EV to EBITDA ratio of 9.21, which is also competitive compared to its peers. Additionally, the PEG ratio stands at a notably low 0.20, suggesting that the stock may not be justified at its current price level. In comparison to its peers, MannKind Corp. has a significantly higher P/E ratio of 38.35, while Ligand Pharmaceuticals, Inc. shows a negative P/E of -67.27, highlighting the varying valuations within the industry. The stock has underperformed against the S&P 500 over multiple periods, with a 1-year return of -14.38% compared to the index's 14.08%, reinforcing the notion that Innoviva, Inc. may not be a compelling inves...

Innoviva, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Market Landscape

2025-10-20 16:18:53

Innoviva, Inc. has recently adjusted its valuation, with a P/E ratio of 15 and a Price to Book Value of 3.16. The company demonstrates strong operational efficiency, reflected in its EV to EBIT and EV to EBITDA ratios, alongside notable returns on capital and equity compared to its peers.

Is Innoviva, Inc. overvalued or undervalued?

2025-10-20 12:26:22

As of 17 October 2025, the valuation grade for Innoviva, Inc. has moved from attractive to expensive, indicating a shift towards overvaluation. The company is currently considered overvalued based on its P/E ratio of 15, which is lower than its peer average of approximately 16.41, and an EV to EBITDA ratio of 9.21, which is also competitive compared to its peers. Additionally, the PEG ratio stands out at 0.20, suggesting strong growth potential relative to its price. In comparison to its peers, Ligand Pharmaceuticals, Inc. has a significantly higher P/E ratio of 67.27, while MannKind Corp. shows a P/E of 38.35, both indicating a higher valuation in the market. Despite Innoviva's strong ROCE of 28.07% and ROE of 20.43%, its recent stock performance has lagged behind the S&P 500, with a year-to-date return of -0.46% compared to the S&P 500's 13.30%. This underperformance reinforces the notion that Innoviva, ...

Is Innoviva, Inc. overvalued or undervalued?

2025-10-19 12:03:55

As of 17 October 2025, the valuation grade for Innoviva, Inc. has moved from attractive to expensive, indicating a shift towards overvaluation. The company appears overvalued based on its current metrics, with a P/E ratio of 15, a Price to Book Value of 3.16, and an EV to EBITDA of 9.21. In comparison, its peer Ligand Pharmaceuticals, Inc. has a significantly higher P/E ratio of 16.41, while MannKind Corp. shows a P/E of 38.35, suggesting that Innoviva's valuation may not be justified relative to its peers. The company's ROCE stands at a strong 28.07%, and its ROE is 20.43%, indicating solid profitability. However, these strengths are overshadowed by its high valuation ratios. Although specific return data is not available, the absence of comparative performance metrics against the S&P 500 adds to the uncertainty surrounding its current valuation status. Overall, Innoviva, Inc. is deemed overvalued in the ...

Innoviva, Inc. Stock Plummets to New 52-Week Low of $16.52

2025-10-16 18:21:32

Innoviva, Inc. has reached a new 52-week low of USD 16.52, significantly down from its high of USD 22. The company, with a market cap of USD 1,944 million, shows a 9.1% gain over the past year, lower than the S&P 500's 13.39%. Innoviva has a P/E ratio of 15.00 and a low debt-to-equity ratio of 0.03, indicating conservative leverage. The return on equity is 16.58%, but the company does not offer dividends.

Innoviva, Inc. Hits 52-Week Low at USD 16.59 Amid Market Volatility

2025-10-15 17:01:14

Innoviva, Inc. has reached a new 52-week low of USD 16.59, contrasting with its 1-year performance of 4.58%. With a market cap of USD 1,944 million, a P/E ratio of 15.00, and a low debt-to-equity ratio of 0.03, the company emphasizes reinvestment over dividends.

Innoviva, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Fluctuations

2025-09-23 16:00:44

Innoviva, Inc., a small-cap pharmaceutical company, has experienced stock fluctuations, with a recent closing price of $19.19. The stock's performance has varied, showing a year-to-date return of 9.74%, while trailing behind the S&P 500. Recent evaluations highlight the company's position amid market challenges.

View All News